Conference Support

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology

Medical Writer: Stijn van den Borne, MSc
Updated: 11 September 2017

YOU MAY ALSO LIKE

ERAS guidelines for antenatal and preoperative care in caesarean delivery 1

ERAS guidelines for antenatal and preoperative care in caesarean delivery

Dr Paul Kessler - Euroanaesthesia 2018 - Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements

©Aspen Pharmacare

Awake, Sedated or Anaesthetised for Regional Anaesthesia Block Placements

Dr Ngai LIU - Euroanaesthesia 2018 - Closed-Loop or Automated Titration of IV Anaesthesia Impact on Routine Anaesthesia

©Aspen Pharmacare

Closed-Loop or Automated Titration of IV Anaesthesia: Impact on Routine Anaesthesia

Meta-analysis TIVA with propofol lowers post-operative nausea, vomiting, and pain

Meta-analysis: TIVA with propofol lowers post-operative nausea, vomiting, and pain

Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology.

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology (CSA), held from 7-10 September 2017 in Zhengzhou, Henan Province, PR China.

We would like to extend our gratitude to the inviting partner, the CSA, and doctors for making time to meet our medical writer.

The Annual Meeting of the CSA, the official anaesthetist chapter of the Chinese Medical Association, is the largest anaesthesiology meeting in China.

1 2 3 4 5 6 7 8 9

© Copyright 2017 – MediPaper – 25th Annual Meeting of the Chinese Society of Anaesthesiology – CSA2017 – 中华医学会第25 次全国麻醉学术年会

You may also like

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

Olaparib plus Bevacizumab as Maintenance Therapy in Ovarian Cancer

ADDING RIBOCICLIB TO FULVESTRANT IMPROVES THE SURVIVAL OF ADVANCED BREAST CANCER PATIENTS MONALEESA-3

Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

paclitaxel, cobimetinib, Cotellic, MEK, Exelixis, atezolizumab, Tecentriq, nab-paclitaxel pembrolizumab, Keytruda, Merck, MSD, eribulin mesylate, Halaven, pertuzumab, trastuzumab, Herceptin, Perjeta, docetaxel, Taxotere, Sanofi, trastuzumab-dkst, Ogivri, Mylan, Biocon, margetuximab, MacroGenics, capecitabine, Xeloda, Genentech, gemcitabine, Gemzar, vinolrebine, pyrotinib, Jiangsu HengRui Medicine, neratinib, Nerlynx, Puma, lapatinib, Tykerb, carboplatin, T-DM1, ado-trastuzumab emtansine, Kadcyla doxorubicin, cisplatin, olaparib, Lynparza, cyclophosphamide, epirubicin, Ellence, Pharmorubicin, letrozole, Femara, Novartis, AI, NSAI, capivasertib, capivasertib, AZD5363, AKT, hormonal therapy, endocrine therapy, CDK4/6, RAD001, mTOR, fulvestrant, Faslodex, abemaciclib, Verzenio, Eli Lilly, ribociclib, Kisqali, goserilin, Zoladex, AstraZeneca, everolimus, Afinitor, exemestane, Aromasin, Pfizer, palbociclib, Ibrance, #ASCO2019, AKT1, AZ, BRCA, chemotherapy, CNS metastases, ER-positive, ESR1, GnRH, HER2-negative, HER2-positive, HR-positive, LABC, neoadjuvant, OfS, PARP, PARPi, pCR, PD-L1, postmenopausal, PR-positive, premenopausal, RB1, TAC, taxane, TNBC, trastuzumab, triptorelin

ASCO 2019 Breast Cancer: The ASCO19 breast cancer track summarised

Venetoclax FDA approved for CLL and SLL

FDA approves avelumab plus axitinib for renal cell carcinoma

Ramucirumab FDA approved for hepatocellular carcinoma

T-DM1 FDA approved for early breast cancer

Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2017 – MediPaper – CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology

Therapeutic Areas